CRISPR Therapeutics AG (CRSP)
Fair ValueFundamental
27
Price
$55.32
Market Cap
$5.39B
Part 1 · What the company is worth
Overview
CRISPR Therapeutics develops medicines based on gene editing — cutting and correcting DNA directly inside cells rather than treating symptoms with a conventional drug. Its lead product, Casgevy, a one-time treatment for sickle cell disease and beta thalassemia, is approved and sold by its partner Vertex Pharmaceuticals. Beyond Casgevy, the company runs its own pipeline of experimental gene-edited cell therapies and in-vivo editing programmes aimed at cardiovascular, metabolic, autoimmune, oncology and other rare diseases.
How it makes money
CRISPR Therapeutics earns most of its money not from selling a product itself, but from its share of Casgevy's profits and losses under a 60/40 arrangement with Vertex, which manufactures, markets and books the product's own commercial revenue. The company also collects upfront and milestone payments from research collaborations. Its own pipeline programmes are pre-revenue and consume cash through clinical trials, so overall revenue is small, uneven, and depends on Vertex's commercial execution rather than on sales the company controls directly.
Key risks
- Early-stage gene editing technology and clinical trial risk — The company states that CRISPR/Cas9 gene editing is a relatively new technology with a limited history of clinical trials, making it hard to predict how long or how much it will cost to develop new product candidates, or whether past trial results will be repeated in future studies.
- Regulatory caution toward gene therapy — The company states that regulators including the FDA and EMA have shown caution toward gene therapy, and that ethical and legal concerns could lead to additional restrictions on developing or commercializing its product candidates.
- Dependence on Vertex for Casgevy — Vertex leads global development, manufacturing and commercialization of Casgevy and books its revenue directly, sharing program costs and profits 60/40 with CRISPR Therapeutics, which does not control the pace or quality of the product's commercial rollout.
- Intellectual property uncertainty — The company states it faces uncertainty over intellectual property protection for its gene editing technology, including third-party patent rights relevant to CRISPR/Cas9 that have been the subject of ongoing interference proceedings.
Customer concentration
The company does not report a numeric customer split, but structurally almost all near-term revenue depends on a single partner, Vertex, which leads Casgevy's global development, manufacturing and commercialization.
The case for
Buyers argue that Casgevy's approval validates CRISPR Therapeutics' gene editing platform commercially, that its cash position of nearly $2 billion funds a broad pipeline of in-vivo and cell-therapy programmes without near-term financing risk, and that success in any one of several disease areas could open a large new market.
The case against
Sellers worry that Casgevy revenue is small and controlled by Vertex rather than by CRISPR Therapeutics itself, that gene editing remains a young technology regulators treat cautiously, and that the pipeline behind Casgevy is still pre-revenue and could consume cash for years before any of it reaches the market, if it ever does.
Written by the editors, published on August 18, 2026
Direct competitors
Who this company fights with for the same customers
Generated on September 18, 2026 with claude-haiku-4-5 — shared with all users
The closest peer on CRISPR/Cas9 medicine: both companies are building in vivo, lipid-nanoparticle-delivered gene-editing therapies for rare and cardiovascular diseases, competing for the same patients, trial sites and pharma partnerships.
Beam's base-editing therapy for sickle cell disease targets exactly the patient population CRISPR Therapeutics addresses with Casgevy, and both also pursue liver-directed in vivo editing.
Editas develops gene-editing therapies that raise fetal haemoglobin in blood stem cells — the same biological mechanism and the same sickle cell and beta-thalassaemia market Casgevy serves.
Its approved therapy Lyfgenia is the only other one-time genetic medicine for sickle cell disease on the US market, so it competes with Casgevy patient by patient at the same treatment centres.
Caribou builds gene-edited, off-the-shelf allogeneic CAR-T cell therapies for blood cancers and autoimmune disease — the same field as CRISPR Therapeutics' allogeneic CAR-T programmes.
Prime Medicine's prime-editing platform chases the same genetic diseases with a rival editing technology, competing for the same future patients and for partner and investor capital.
Balance Sheet & Liquidity
Revenue
$13M
Trailing 12 months (through 6/30/2026)
Net Income
$-451M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$-346M
Total Equity
$1.92B
Total Liabilities
$343M
Current Ratio
17.85
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$65.80
Current Price
$55.32
Margin of Safety
+15.9%
Fair Value Range
$42.77 - $88.83
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-30.3%
P/B Ratio
3.06
P/FCF
-
Gross Margin
-
ROIC
-16.8%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-16.8%
WACC
13.2%
ROIC − WACC
-30.0 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (7)
- Price CAGR 10.66%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Revenue Growth 5Y 38.0%
- Analyst Consensus 61% Buy
- Earnings Surprise avg 3.3%
Failed (11)
- EPS shows upward trend
- ROIC -16.8%
- P/B Ratio 3.06
- Operating Margin -3990.0%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Overvalued)
- ROE -24.4%
- Share Dilution 6.5%
- Net Margin Trend -3368.7% vs -1229.4%
- Piotroski F-Score 1/9
Unavailable (9)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Serious financial concerns
Earnings Quality
Low quality: investigate accounting
Share Dilution
Issuing new shares, diluting ownership
Institutional Holdings
No institutional filings reported for this company.
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Dr. Samarth Kulkarni Ph.D. | CEO & Chairman | 47 |
| Dr. Raju Yashaswi Prasad Ph.D. | Chief Financial Officer | 41 |
| Mr. James R. Kasinger J.D. | General Counsel & Secretary | 53 |
| Dr. Naimish Patel C.M., M.D. | Chief Medical Officer | 53 |
| Mr. Shaun Foy CFA | Co-Founder | - |
| Dr. Emmanuelle Marie Charpentier Ph.D. | Co-Founder & Scientific Advisory Board Member | - |
| Dr. Craig C. Mello Ph.D. | Scientific Founder & Advisory Board Member | - |
| Dr. Chad A. Cowan Ph.D. | Scientific Founder | 53 |
| Dr. Matthew Porteus M.D., Ph.D. | Scientific Founder & Advisory Board Member | 60 |
| Dr. Daniel G. Anderson Ph.D. | Scientific Founder & Advisory Board Member | 55 |
Audit Risk
8
Board Risk
8
Compensation Risk
10
Shareholder Rights Risk
2
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-12
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-08-03
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-08-03
via SEC EDGAR
Income History
via SEC EDGAR
Latest News
Recent headlines for CRSP, sourced from Markets Gazette.
- 3/10/2026NEGATIVEThis Is Why CRISPR Therapeutics Stock Is Tumbling on Tuesday
CRISPR Therapeutics AG experienced a significant stock price decline on Tuesday, as current shareholders faced an unexpected development. While the specific catalyst is not detailed in the provided snippet, the market reaction suggests a negative event has occurred, potentially related to clinical trial results, regulatory hurdles, or competitive pressures. Investors are advised to monitor further announcements for clarity on the situation impacting the biotechnology firm's valuation.
- 3/2/2026NEUTRALIs CRISPR Therapeutics Stock Too Risky to Buy Right Now?
CRISPR Therapeutics (CRSP) finds itself at a pivotal juncture, presenting a complex picture for investors. While the biotechnology firm currently struggles with profitability, a common challenge for companies in its developmental stage, it has achieved a significant milestone: the approval of a gene therapy treatment. This approval unlocks substantial future potential, positioning CRISPR as a key player in innovative medical solutions. However, the immediate lack of earnings raises questions about short-term financial stability versus long-term growth prospects. Investors must weigh the inherent risks of an unprofitable enterprise against the promising outlook of its groundbreaking therapeutic advancements.
via Markets Gazette